2026 Mark A. Lemmon: Biology and Biochemistry Researcher – H-Index, Publications & Awards

D-Index & Metrics

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	98	1630	1468	910	805	270	45251

Discipline name

D-Index

World Ranking

Current World Ranking

National Ranking

Current National Ranking

Publications

Citations

Biology and Biochemistry

1630

1468

910

805

270

45251

Biology and Biochemistry

D-Index

Citations

45251

World Ranking

1630

National Ranking

910

Research.com Recognitions

2016 - Fellow of the Royal Society, United Kingdom

Overview

Mark A. Lemmon is affiliated with Yale University in the United States. Their research primarily spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine, with a strong focus on Molecular Biology, Oncology, Immunology, Pulmonary and Respiratory Medicine, and Neurology.

The scientist's recent publications include the following papers:

Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases (2020, Molecular Cell)
Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics (2020, Science Signaling)
Glioblastoma mutations alter EGFR dimer structure to prevent ligand bias (2022, Nature)
Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers (2021, Cancer Research)
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations (2020, Cancer Research)

Frequent co-authors include:

Yuko Tsutsui (11 co-publications)
Kumar Dilip Ashtekar (9 co-publications)
Steven E. Stayrook (8 co-publications)
Joshua B. Sheetz (7 co-publications)
Courtney M. Smith (7 co-publications)

Mark A. Lemmon has published extensively in the following venues:

bioRxiv (Cold Spring Harbor Laboratory) (7 publications)
Nature Communications (3 publications)
Nature (2 publications)
Cancer Research (2 publications)
Biochemical Journal (2 publications)

The main research topics addressed include:

Lung Cancer Treatments and Mutations
Cancer therapeutics and mechanisms
HER2/EGFR in Cancer Research
Neuroblastoma Research and Treatments
PI3K/AKT/mTOR signaling in cancer
Monoclonal and Polyclonal Antibodies Research
Galectins and Cancer Biology

Mark A. Lemmon was awarded the title of Fellow of the Royal Society, United Kingdom, in 2016.

Best Publications

Cell signaling by receptor-tyrosine kinases

Mark A. Lemmon;Joseph Schlessinger

7259
Citations
Membrane recognition by phospholipid-binding domains.

Mark A. Lemmon

1738
Citations
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors

Antony W. Burgess;Hyun Soo Cho;Hyun Soo Cho;Charles Eigenbrot;Kathryn M. Ferguson

1255
Citations
EGF Activates Its Receptor by Removing Interactions that Autoinhibit Ectodomain Dimerization

Kathryn M. Ferguson;Mitchell B. Berger;Jeannine M. Mendrola;Hyun Soo Cho

1089
Citations
Signal-dependent membrane targeting by pleckstrin homology (PH) domains

Mark A. Lemmon;Kathryn M. Ferguson

997
Citations
Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation.

T. Spivak-Kroizman;M.A. Lemmon;I. Dikic;J.E. Ladbury

885
Citations
Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain

Kathryn M. Ferguson;Mark A. Lemmon;Joseph Schlessinger;Paul B. Sigler

784
Citations
Phosphoinositide Recognition Domains

Mark A. Lemmon

774
Citations
Activation of phospholipase Cγ by PI 3‐kinase‐induced PH domain‐mediated membrane targeting

M. Falasca;S.K. Logan;V.P. Lehto;G. Baccante

747
Citations
Specific and high-affinity binding of inositol phosphates to an isolated pleckstrin homology domain

Mark A. Lemmon;Kathryn M. Ferguson;Ronan O'Brien;Paul B. Sigler

733
Citations
Regulation of signal transduction and signal diversity by receptor oligomerization.

Mark A. Lemmon;Joseph Schlessinger

710
Citations
Sequence specificity in the dimerization of transmembrane alpha-helices.

Mark A. Lemmon;John M. Flanagan;Herbert R. Treutlein;Jian Zhang

680
Citations
Regulation of growth factor activation by proteoglycans: What is the role of the low affinity receptors?

Joseph Schlessinger;Irit Lax;Mark Lemmon

637
Citations
Glycophorin A dimerization is driven by specific interactions between transmembrane alpha helices

M.A. Lemmon;J.M. Flanagan;J.F. Hunt;B.D. Adair

616
Citations
PH Domains: Diverse Sequences with a Common Fold Recruit Signaling Molecules to the Cell Surface

Mark A Lemmon;Kathryn M Ferguson;Joseph Schlessinger

611
Citations
Specificity and Promiscuity in Phosphoinositide Binding by Pleckstrin Homology Domains

Jennifer M. Kavran;Daryl E. Klein;Anthony Lee;Marco Falasca

564
Citations
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation

Fumin Shi;Shannon E. Telesco;Yingting Liu;Ravi Radhakrishnan

537
Citations
Two EGF molecules contribute additively to stabilization of the EGFR dimer

Mark A. Lemmon;Zimei Bu;John Edward Simon Durham Ladbury;Min Zhou;Min Zhou

497
Citations
The EGFR Family: Not So Prototypical Receptor Tyrosine Kinases

Mark A. Lemmon;Joseph Schlessinger;Kathryn M. Ferguson

494
Citations
SH2 and PTB domains in tyrosine kinase signaling

Joseph Schlessinger;Mark A. Lemmon

465
Citations